Mabvax Therapeutics Holdings Inc

Find more results for Philip R Kaplan´┐Ż

Officers and directors

J. David Hansen
Chairman of the Board, President, Chief Executive Officer
Gregory P. Hanson
Chief Financial Officer
Wendy K. Wee
Principal Accounting Officer, Vice President - Finance, Controller
Philip O. Livingston M.D.
Chief Science Officer, Director
William P. Kaplan Esq.
Vice President, General Counsel, Corporate Secretary, Vice President - Legal Affairs
Wolfgang W. Scholz Ph.D.
Vice President - Antibody Discovery
Steven R. Schow Ph.D.
Vice President - Research
Kenneth M. Cohen
Robert E. Hoffman
Paul V. Maier


11588 Sorrento Valley Rd Ste 20
SAN DIEGO, CA 92121-1336
United States - Map
+1-858-2599405 (Phone)

Website links

MabVax Therapeutics Holdings, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of human monoclonal antibody products and vaccines for the treatment of a variety of cancers. The Company has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The Company’s lead antibody candidate, 5B1, is being developed for the treatment of pancreatic cancer. The Company has completed additional Phase I vaccine clinical trials in melanoma, ovarian cancer, and small cell lung cancer. The Company is also developing the 5B1 antibody conjugated to a radiolabel as positron Emission tomography imaging agent to assist in the diagnosis of pancreatic cancer.

Related companies

* Delayed by up to 20 minutes -  Disclaimer